Aflibercept (Eylea®) Injection

Eylea (aflibercept) is covered for FDA‑approved ophthalmic indications (neovascular AMD, RVO‑related macular edema, DME, DR) and select compendial off‑label neovascular ocular uses; treatments outside these listed indications are excluded. Approval (up to 12 months) requires a documented diagnosis, administration by or under an ophthalmologist, and documentation supporting adherence to indication‑specific dosing/frequency (AMD: 2 mg q4wk ×3 then q8wk; RVO: 2 mg q4wk; DME/DR: 2 mg q4wk ×5 then q8wk).

"Neovascular (wet) age-related macular degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.